ProCE Banner Activity

Phase III PERSEUS: MRD Analysis of VRd ± Daratumumab in Newly Diagnosed Multiple Myeloma Eligible for ASCT

Conference Coverage
Slideset

In this analysis of the phase III PERSEUS trial, higher rates of deep measurable residual disease (MRD 10-6) and sustained MRD negativity were achieved with daratumumab plus VRd induction and consolidation followed by daratumumab/lenalidomide maintenance compared with VRd followed by lenalidomide in patients with transplant-eligible newly diagnosed multiple myeloma.

Released: June 07, 2024

Expiration: June 06, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi